Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fate of aortic bioprostheses: An 18-year experience

Published byAmberlynn Stanley Modified over 5 years ago

Similar presentations

Presentation on theme: "Fate of aortic bioprostheses: An 18-year experience"— Presentation transcript:

1 Fate of aortic bioprostheses: An 18-year experience
Alessandro Piccardo, MD, Jean David Blossier, MD, Alexandre Le Guyader, MD, Isabelle Orsel, MD, Seifeddine Sekkal, MD, Elisabeth Cornu, MD, Marc Laskar, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 151, Issue 3, Pages e1 (March 2016) DOI: /j.jtcvs Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

2 Figure 1 Overall survival after aortic valve replacement with the Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis, showing nonemergent isolated aortic valve replacement (black line) and the overall population (red line). The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

3 Figure 2 Freedom from reintervention for structural valve deterioration after aortic valve replacement with Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis. SVD, Structural valve deterioration. The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

4 Figure 3 Freedom from reoperation for endocarditis on operated valve after aortic valve replacement with Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis. The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

5 Figure 4 Freedom from echocardiographic signs of structural valve deterioration (SVD) (ie, mean transprosthetic gradient >40 mm Hg or aortic regurgitation greater than mild) after aortic valve replacement with Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis. The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

6 Figure 5 Freedom from echocardiographic signs of structural valve deterioration (SVD) (ie, mean transprosthetic gradient >40 mm Hg or aortic regurgitation greater than mild) after aortic valve replacement with Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis, according to severe (black line), moderate (blue line), or no (red line) patient–prosthesis mismatch. The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

7 Figure 6 Freedom from echocardiographic signs of structural valve deterioration (SVD) (ie, mean transprosthetic gradient >40 mm Hg or aortic regurgitation greater than mild) after aortic valve replacement with Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis, according to prosthesis size 19 (blue line) or size >19 (red line). The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

8 Freedom from structural valve deterioration (SVD) according to size of prosthesis.
The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Download ppt "Fate of aortic bioprostheses: An 18-year experience"

Similar presentations

Tubular heart valves: A new tissue prosthesis design—Preclinical evaluation of the 3F aortic bioprosthesis James L. Cox, MD, Niv Ad, MD, Keith Myers, BS,

Tubular heart valves: A new tissue prosthesis design—Preclinical evaluation of the 3F aortic bioprosthesis James L. Cox, MD, Niv Ad, MD, Keith Myers, BS,
W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P
Transcatheter aortic valve replacement in patients with severe aortic stenosis who are at high risk for surgical complications: Summary assessment of.

Transcatheter aortic valve replacement in patients with severe aortic stenosis who are at high risk for surgical complications: Summary assessment of.
Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 

Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 
Of mice and men and surgical transcatheter aortic valve insertion

Of mice and men and surgical transcatheter aortic valve insertion
The fate of small-size pericardial heart valve prostheses in an older patient population  Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,

The fate of small-size pericardial heart valve prostheses in an older patient population  Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,
Aortic valve replacement in low-flow, low-gradient aortic stenosis: Left ventricular ejection fraction matters  Victor Dayan, MD, PhD, Philippe Pibarot,

Aortic valve replacement in low-flow, low-gradient aortic stenosis: Left ventricular ejection fraction matters  Victor Dayan, MD, PhD, Philippe Pibarot,
Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study  Vincent Chan,

Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study  Vincent Chan,
Paravalvular regurgitation after conventional aortic and mitral valve replacement: A benchmark for alternative approaches  Brett F. Duncan, MD, Patrick.

Paravalvular regurgitation after conventional aortic and mitral valve replacement: A benchmark for alternative approaches  Brett F. Duncan, MD, Patrick.
An unusual case of severe aortic valve stenosis in an adult caused by aortic valve inflammatory myofibroblastic tumor  Dong Zhao, MD, Chunsheng Wang,

An unusual case of severe aortic valve stenosis in an adult caused by aortic valve inflammatory myofibroblastic tumor  Dong Zhao, MD, Chunsheng Wang,
Scott Goldman, MD, Anson Cheung, MD, Joseph E. Bavaria, MD, Michael R

Scott Goldman, MD, Anson Cheung, MD, Joseph E. Bavaria, MD, Michael R
Lars G. Svensson, MD, PhD, Lillian H. Batizy, MS, Eugene H

Lars G. Svensson, MD, PhD, Lillian H. Batizy, MS, Eugene H
Management of concomitant mild to moderate functional mitral regurgitation during aortic valve surgery for severe aortic insufficiency  Ju Yong Lim, MD,

Management of concomitant mild to moderate functional mitral regurgitation during aortic valve surgery for severe aortic insufficiency  Ju Yong Lim, MD,
Harald C. Eichstaedt, MD, Jerry Easo, MD, Tobias Härle, MD, Otto E

Harald C. Eichstaedt, MD, Jerry Easo, MD, Tobias Härle, MD, Otto E
When is the Ross operation a good option to treat aortic valve disease?  Tirone E. David, MD, Anna Woo, MD, Susan Armstrong, MSc, Manjula Maganti, MSc 

When is the Ross operation a good option to treat aortic valve disease?  Tirone E. David, MD, Anna Woo, MD, Susan Armstrong, MSc, Manjula Maganti, MSc 
Transapical transcatheter aortic valve-in-valve implantation: Clinical and hemodynamic outcomes beyond 2 years  Jian Ye, MD, FRCSC, John G. Webb, MD,

Transapical transcatheter aortic valve-in-valve implantation: Clinical and hemodynamic outcomes beyond 2 years  Jian Ye, MD, FRCSC, John G. Webb, MD,
Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age  Torsten Christ,

Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age  Torsten Christ,
The fate of small-size pericardial heart valve prostheses in an older patient population  Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,

The fate of small-size pericardial heart valve prostheses in an older patient population  Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,
Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: Weighing lifetime anticoagulant-related event risk against.

Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: Weighing lifetime anticoagulant-related event risk against.
Reoperative “valve-in-valve” transapical transcatheter mitral valve replacement in a high-risk patient with a recent transapical transcatheter aortic.

Reoperative “valve-in-valve” transapical transcatheter mitral valve replacement in a high-risk patient with a recent transapical transcatheter aortic.

Similar presentations

Ads by Google